The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales. Pfizer has made progress, especially on the clinical and regulatory ...

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. Vandana Singh Qorvo Soars 7% After ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...

Pfizer (NYSE: PFE) stock price has crashed hard in the past ... and 40.5. The weekly chart shows that the PFE share price has ...

At Stock Options Channel ... as well as studying the business fundamentals becomes important. Below is a chart showing PFE's trailing twelve month trading history, with the $27.00 strike ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other ... an optimistic yet cautious outlook for the stock market next year. Lee anticipates that ...